Among these markers, BRCA1-associated protein-1 (BAP1), prostate-specific membrane antigen (PSMA), vascular endothelial growth factor receptor 3 (VEGFR3), platelet-derived growth factor receptor α (PDGFRα), and phosphorylated S6 (pS6) demonstrated a high concordance ratio (>0.7), regardless of different metastatic tissues and different metastatic lesions within the tumor. This evidence concerns the gene BAP1 and neoplasm.